JUDE EMELUMBA: Open Payments
NPI 1396185567 · TRENTON, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$468 in 24 payments from 8 companies in 2025. Trend: 2023 $539 · 2024 $386 · 2025 $468
Food & beverage: $468
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 4 | $129 |
| Neurocrine BioSciences, Inc. | 4 | $74 |
| E.R. Squibb & Sons, L.L.C. | 4 | $72 |
| ABBVIE INC. | 4 | $61 |
| Janssen Pharmaceuticals, Inc | 3 | $46 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $18 |
Products named: Qelbree, INGREZZA, COBENFY, VRAYLAR, INVEGA SUSTENNA, CAPLYTA, UZEDY, AUSTEDO XR.
Industry payments across NJ — which companies pay providers there.
